Actively Recruiting
Evaluating Immune Response to Different Extended Dosing Schedules of Euvichol-S Oral Cholera Vaccine in Nairobi, Kenya Phase IV Randomized Trial Comparing 2-Week, 3-Month, and 12-Month Intervals
Led by Albert B. Sabin Vaccine Institute · Updated on 2026-03-23
1071
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the immune response to different dosing schedules of the Euvichol-S oral cholera vaccine in Kenya, where cholera outbreaks remain a serious health concern, especially among children under 10 years old. This Phase IV randomized trial compares the standard 2-week dosing interval with extended intervals of 3 months and 12 months to determine which schedule provides effective and lasting immunity. The trial aims to support improved vaccination strategies for cholera prevention in high-risk areas such as the Mukuru informal settlement in Nairobi. Participants are randomly assigned to one of three groups receiving the Euvichol-S vaccine either 2 weeks, 3 months, or 12 months apart. The study includes three age groups 1-4 years, 5-14 years, and 15 years or older. Follow-up visits vary by group, with scheduled visits at vaccination times and additional visits at 14 days post-second dose, 6 months, 12 months, and 18 months after enrollment. Blood samples are collected to measure immune responses, including plasma vibriocidal geometric mean titers and other antibody markers. A sub-cohort of children will have additional detailed immune testing. During the 18-month follow-up, participants undergo regular assessments including medical history, physical exams, and blood draws to monitor immune response and vaccine safety. Researchers measure the primary outcome of immune response two weeks after the second vaccine dose and track antibody levels, cholera incidence, and any adverse events over time. The study also collects data on memory B cells and plasmablasts in children to understand long-term immunity. This trial provides important information on vaccine dosing schedules that could improve cholera control efforts in endemic regions.
CONDITIONS
Brief Title
Extended Dosing Intervals Trial for Oral Cholera Vaccine, Kenya
Research Team
S
Samuel Kariuki, BVM, PhD
C
Cecilia Mbae, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here